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Abstract 
  
Contrary to popular belief, memory loss and other cognitive abilities severe enough to 
interfere with daily life are not a normal part of aging.  Worldwide, 50 million people are living 
with a degenerative brain disease known as dementia. 1 In the U.S., 5.7 million Americans are 
living with the most common form of dementia: Alzheimer’s disease (AD).1 AD is a type of 
dementia that causes problems with memory, thinking, and behavior. 1 It is often difficult to 
distinguish depression in older adults without cognitive changes versus depression in those 
affected with Alzheimer’s dementia.  Depression is one of the most frequent psychiatric 
complications of AD, affecting as many as 50% of patients.3 To address this disparity, one must 
first understand the criteria in diagnosing depression in AD.   
Current guidelines such as the National Institute of Mental Health-depression in 
Alzheimer’s disease (NIMH-dAD) and the Cornell Scale for Depression in Dementia (CSDD) have 
been used to diagnose depression in AD.3 Once the diagnosis of depression in AD has been made, 
consideration of effective treatment is required.  Depression in AD is associated with greater 
morbidity and mortality, which does not only affect the patient but the families and caregivers, 
and society as a whole. 2,3 The estimated societal costs due to AD are between $100 billion per 
year, and are projected to double by 2020 and triple by 2040.4,5 In addition, depression in AD 
may also be associated with increased risk of suicide.6  
This review evaluated a Cochrane review as well as two other clinical trials to examine the 
efficacy of SSRI’s at reducing depressive symptoms in AD.  The conclusion suggested that there is 
weak evidence to support the use of SSRI’s in the treatment of patients with AD and depression.  
However, this conclusion is based on a small number of studies with small sample sizes.11 In order 
to decrease morbidity and mortality among patients with AD who suffer with depression, there 
must be further research to support the efficacy of SSRI’s. 
 
 
 
 
 
Background 
Cognitive function that leads to significant impairment or change in functioning is not a 
normal part of aging and is not inevitable.  For instance, a 78-year-old woman who spends an 
hour finishing a crossword puzzle that used to take her 20 minutes is considered to be in a normal 
spectrum of aging.  However, a 75-year-old man who repeatedly loses his car keys and has missed 
a couple doctor’s appointments he forgot to write down is considered to have mild cognitive 
impairment.12  
Dementia interferes with one’s activities of daily living and is associated with decline in 
executive functioning.  For instance, one may no longer possess the capacity to responsibly 
manage one’s own finances, which can have serious potential consequences.  Dementia in older 
adults is also characterized as insidious in onset with a stable course and is associated with clear 
consciousness.  Persons with dementia also have a relatively normal attention span, possess a 
global impairment in non-fluctuating cognition in terms of conceptual organization (with 
hallucinations usually absent), possess normal psychomotor activities, and have reduced 
vocabulary.13 
Although there are many kinds of dementia, this paper will focus on AD, which is 
considered a more severe form of dementia.  AD is characterized as a steady, gradual decline in 
its neurological processes, and while non-Alzheimer’s dementia is characterized as possessing 
normal psychomotor activities, there is psychomotor dysfunction in AD.  In the early stages of 
AD, memory dysfunction is usually the first symptom followed by apathy, depression, and anxiety.  
Psychotic symptoms such as delusions, hallucinations, agitation, wandering, and aggression are 
more prevalent during the middle stages of AD.13 
According to the Alzheimer’s Association, “for a person to be diagnosed with depression 
in AD, he or she must have either depressed mood (sad, hopeless, discouraged or tearful) or 
decreased pleasure in usual activities, along with two or more of the following symptoms for two 
weeks or longer: 1) social isolation or withdrawal, 2) disruption in appetite that is not related to 
another medical condition, 3) disruption in sleep, 4) agitation or slowed behavior, 5) irritability, 
6) fatigue or loss of energy, 7) feelings of worthlessness or hopelessness, or inappropriate or 
excessive guilt, and 8) recurrent thoughts of death, suicide plans or a suicide attempt.”14  
According to the Alzheimer’s Association, depression in AD does not always look like 
depression in people without AD.  The ways in which they differ is that depression in a person 
with AD: 1) may be less severe, 2) may not last as long and symptoms may come and go, and 3) 
the person with AD may be less likely to talk about or attempt suicide.1 However, depression in 
older adults not affected by AD is characterized as: 1) gradual in onset with a stable course, 2) 
clear consciousness, 3) difficulty in concentration, 4) global slowing in cognition, 5) decreased 
energy, 6) difficulty with activities, 7) latency in speech with low volume, and 8) general slowing 
of conceptual organization.12  Depression in the elderly not affected by AD may also present 
atypically such as a lack of sadness, hyperactivity, and somatic complaints such as appetite 
changes, vague gastrointestinal symptoms, constipation, and sleep disturbances.12  
It is important that we understand how depression affects patients with AD because it 
affects morbidity and mortality.  According to Sergio Starkstein and Romina Mizrahi, “depression 
is one of the most frequent comorbid psychiatric disorders in Alzheimer dementia and other 
dementias, and is associated with poorer quality of life, greater disability in ADLs, a faster 
cognitive decline, a high rate of nursing home placement, relatively higher mortality and a higher 
frequency of depression and burden in caregivers. Depression in AD is markedly underdiagnosed 
and most patients with depression are either not treated or are on subclinical doses of 
antidepressants.”15  
The approach to treatment for depression in AD should start with an evaluation to 
characterize the nature and cause of the depressive symptoms.8 Evaluation of depression in AD 
should consist of thorough history taking, mental status examination, laboratory studies, and 
rating on standardized measures for depression in dementia, such as the CSDD or the Dementia 
Mood Assessment Scale (DMAS).3  
Once the diagnosis of depression in AD has been made, from mild to severe depression, 
one should assess the most appropriate treatment options.  For those with mild depression, it 
has been suggested that therapy should start with non-biological interventions, such as the 
provision of pleasant activities.9 Pharmacological management is often used for depression in AD 
patients who do not respond to non-biological interventions alone.  Often times, pharmacological 
management is required for patients with a CSDD score greater than 1210; when the patient is 
suicidal or violent or when the patient is not eating or drinking.3   This review will focus on AD 
patients with depression who require pharmacological treatment for their symptoms.  More 
specifically, this review will focus on the efficacy of selective serotonin reuptake inhibitors (SSRIs) 
at reducing depressive symptoms in comparison to AD patients not taking SSRIs. 
  
Epidemiology 
AD is the most common cause of dementia and one of the leading sources of morbidity 
and mortality in the aging population.  AD is increasingly prevalent with advancing age and it is 
estimated that around 47 million people are affected by dementia.  The onset of AD usually 
occurs at age greater than 65 years old, with a peak incidence between the ages of 75 to 84 years.  
Risk factors for AD include: advanced age, family history, hypertension, dyslipidemia, 
cerebrovascular disease, peripheral atherosclerosis, Type 2 diabetes and obesity, less-active 
lifestyle, brain trauma, and certain medications (e.g. benzodiazepines, anticholinergics, 
antihistamines, opioids).16 
 
Pathophysiology 
Amyloid beta peptides and the tau protein have been implicated in the pathogenesis of 
AD.  Even though the exact pathogenesis of AD remains unclear, what is clear is that all forms of 
AD seem to share the overproduction and/or decreased clearance of a protein called amyloid 
beta peptides.  Amyloid beta peptides are produced by the cleavage of mature protein translated 
from the amyloid precursor protein (APP) gene and cleaved by beta-secretase and gamma-
secretase.16  
AD is thought to be caused by a defect in presenilin, a transmembrane protein that forms 
part of the gamma-secretase complex.  The defect in presenilin starts with genetic mutations in 
the code for making presenilin, presenilin 1 (PSEN1) or presenilin 2 (PSEN2), which causes the 
over-production of amyloid beta or more neurotoxic forms of amyloid beta.  Even though the 
ultimate neurotoxin in AD is debated, experimental evidence highlights small aggregates of 
amyloid beta peptides called oligomers, as opposed to larger aggregates called fibrils that seem 
to contribute to AD.16 
The pathogenesis of AD also involves a second protein, tau.  Tau is a protein that aids in 
the assembly and stabilization of microtubules.  In AD, tau becomes hyper-phosphorylated and 
collects to form paired helical filament (PHF) tau, which is a major component of neurofibrillary 
tangles within the cytoplasm of the neuron.  Experiments have shown that the accumulation of 
this PHF tau is toxic to neurons.  According to J.L. Guo and V.M. Lee, “the transmission of 
pathologic forms of tau between neurons has been proposed to account for the spread of AD in 
the brain, which follows a distinct progression across brain regions as AD advances.”17 
There are also other significant and potentially overlapping pathways that are thought to 
contribute to the pathogenesis of AD.  One example is the human apolipoprotein E (APOE) gene.  
APOE is a pleiotropic lipoprotein involved in multiple cellular processes such as cholesterol 
transport, development, synaptic plasticity, and immune regulation.18 There are three alleles of 
APOE, called epsilon 2 (e2), e3, and e4, and their encoded isoforms also vary.18 It is postulated 
that inheritance of the APOE e4 may increase AD risk is by impairing amyloid beta clearance from 
cerebrum.  
The pathophysiology of depression in AD has also been associated with the possible 
selective loss of noradrenergic cells in the locus ceruleus of the brain.7 Studies have also shown 
that depression is associated with loss of dorsal raphe serotonergic nuclei in Alzheimer’s disease.7 
These findings have implications for the treatment of depression, specifically, about the role of 
manipulation of the relevant neurotransmitter systems in treating AD- associated depression.3 
 
Methods 
 PubMed was searched with the following terms: “depression in Alzheimer’s,” “review of 
SSRI depression Alzheimer's,” “SSRI treatment in Alzheimer’s,” “efficacy of SSRI’s in Alzheimer’s.” 
Google Scholar was also searched for the following terms: “depression in Alzheimer’s,” “SSRI’s 
and Alzheimer’s,” “efficacy of SSRI Alzheimer’s” and “SSRI’s depression in Alzheimer’s.” EBSCO 
was also searched using the following terms: “SSRIs treating depression AND Alzheimer’s.” 
Scopus was also searched using the terms “depression AND Alzheimer’s AND SSRI’s.” 
 Two randomized control trials and a systematic review was also referenced for the clinical 
review of this topic. Studies that involved treatment of temporary behavioral symptoms of 
dementia, such as fluctuating agitation and aggression was excluded.  Studies that included non-
SSRI treatment for depression in Alzheimer’s disease such a tricyclic antidepressants, anti-
psychotics, and electro-convulsive therapy (ECT) was also excluded. Bias was evaluated with the 
Cochrane Risk of Bias Tool and the GRADE (Grades of Recommendation, Assessment, 
Development and Evaluation) system. 
 
Results 
 This review included the evaluation of a Cochrane systematic review of randomized trials, 
as well as two clinical studies that were not included in the systematic review.  Summary tables 
of study results, outcomes, and risk of bias are included in Tables 1, 2, 3 and 4. 
Rosenberg et al. (2010) conducted a randomized, double-blinded treatment with 
sertraline or placebo in their study to assess the efficacy and tolerability of sertraline (an SSRI) 
for depression in AD.  One hundred thirty-one participants from five U.S. medical centers with 
mild-moderate AD (Mini-Mental State Examination scores 10-26) and depression of AD were 
either given a placebo or 100 mg daily of sertraline.   
Efficacy was assessed using logistic regressions and mixed effect models in an intention-
to-treat analysis with imputation of missing data.19 Outcome measures was assessed using the 
Alzheimer’s Disease Cooperative Study-Clinical Global Impression of Change (mADCS-CGIC), 
change in CSDD scores, and remission defined by both mADCS-CGIC score ≤ and CSDD score ≤ 
6.19 The results from their studied showed a mADCS ratings (odd ratio [OR=1.01], 95% confidence 
interval [CI]: 0.52-1.97m p= 0.98), CSDD scores (median difference at 12 weeks 1.2, 95% CI: 1.65-
4.05, p=0.41), and remission to depression at 12 weeks of follow-up (OR=2.06, 95% CI: 0.84-5.04, 
p=0.11) did not differ between the experimental group (those who took sertraline 100 mg daily, 
n=67) versus the control group (placebo, n=64).19  Furthermore, more patients in the 
experimental group reported more adverse outcomes (such as gastrointestinal and respiratory 
symptoms) from treatment than placebo.  In so forth, the study by Rosenberg et al. (2010) 
suggested that 12 weeks of sertraline treatment for depression in AD was not associated with 
clinical improvement and was associated with a higher risk of adverse effects on the 
gastrointestinal and respiratory systems. 
A comprehensive study conducted by Banerjee et al. (2016) consisted of a multi-center, 
randomized, double-blind, placebo-controlled trial to determine the clinical effectiveness of 
sertraline and mirtazapine in reducing depression over 13 weeks.20  The design of their study 
consisted of 326 participants randomly assigned to either placebo (n=111), sertraline (n=107) or 
mirtazapine (n=108) in nine English old-age psychiatry services who met the following criteria: 
probable or possible AD, having depression for over four weeks, and a CSDD score of 8 or above.   
The outcome from their study showed differences in CSDD at 13 weeks from an adjusted 
linear-mixed model: mean difference (95% CI) placebo-sertraline 1.16 (-.023 to 2.78; p=0.102); 
placebo-mirtazapine 0.01 (-1.37 to 1.38; p=0.991); and mirtazapine-sertraline 1.16 (-0.27 to 2.60; 
p=0.112).20 It was also reported that the placebo group had fewer adverse reactions (29/111, 
26%) than sertraline (46/107, 43%) or mirtazapine (44/108, 41%; p=0.017) and that each group 
had an equal mortality rate at 39 weeks.20 The results suggested that the antidepressants are not 
clinically effective (compared with placebo) for clinically significant depression in AD and suggests 
that patients have less gastrointestinal side effects with placebo versus sertraline. 
A 2009 Cochrane systematic review aimed to determine whether antidepressants are 
clinically effective and acceptable for the treatment of patients with depression and dementia.11 
The authors searched the Cochrane Dementia and Cognitive Impairment Group (CDCIG) 
Specialized Register for clinical trials, contacted the medical information departments of 
pharmaceutical companies for ongoing clinical trials, and contacted the authors of the clinical 
trials themselves for additional information.  The selection criteria the authors used consisted of 
non-confounded, double-blind, randomized trials of longer than 4 weeks, comparing any 
antidepressant drug with placebo, for patients diagnosed as having dementia and depression.  
Diagnostic and Statistical Manual of Mental Disorders (DSM), National Institute of Neurological 
and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders 
Association (NINCDS-ADRDA) and International Classification of Disease, Tenth Edition (ICD-10) 
criteria for dementia and depression were met for participants and consisted of patients of any 
age and sex.  Patients suffering from emotional disorders or behavioral problems, but falling short 
of depression (as diagnosed by the recognized criteria) were excluded.11 Any antidepressant 
medication listed in the British National formulary number 49, 2005, section 4.3 compared with 
placebo were included in their review.11  Those trials which studied euphoriants (e.g. 
amphetamines), adjuvants (e.g. lithium), combination treatments (e.g. ‘Motipres’) and studies of 
other drug classes not generally regarded as antidepressants in the first instance (e.g. 
antipsychotics) were excluded.11 
The search methods included trials from CENTRAL, MEDLINE, EMBASE, PsychINFO, 
CINAHL, SIGLE, ISTP, INSIDE, Aslib Index to Theses, Dissertation Abstract, ADEAR, and the National 
Research Register.  The search also included current control trials from the Alzheimer Society, 
GlaxoSmithKline, HongKong Health Services Research Fund, Medical Research Council (MRC), 
NHS R&D Health Technology Assessment Programme, Schering Health Care Ltd., South Australian 
Network for Research on Ageing, U.S. Department of Veterans Affairs Cooperative Studies, and 
the National Institutes of Health.  The authors also searched the Specialized Register of the 
Cochrane Dementia and Cognitive Improvement Group with mention of a detailed list of search 
terms. 
Standard chi-square statistic was used to assess heterogeneity of the treatment effect 
between the trials.  If a test of heterogeneity was negative, then a fixed effects model was used.11 
If there was heterogeneity of the treatment effect in a study, then only the homogenous results 
or a random effects models was used.  The authors also calculated the odds ratio for each trial 
and then a pooled odds ratio across appropriate groups of trials using Mantel-Haenszel methods.  
The weighted mean difference between treatment and control was used for continuous variables. 
Seven studies met inclusion criteria with a total of 1140 participants.  The mean length of 
the studies was 6-12 weeks and dementia was categorized in a variety of ways: “primary 
degenerative dementia, probable Alzheimer’s disease, dementia, Alzheimer’s disease, probable 
Alzheimer’s disease, and primary degenerative dementia of the Alzheimer’s type, with all 
participants meeting DSM criteria for dementia or NINCDS-ADRDA criteria for probable 
Alzheimer’s disease.”11  
Primary outcomes of interest were effect on depression (measured by rating scales), 
effect on cognitive function (measured by psychometric tests), global impression, acceptability 
of treatment (as measured by withdrawal from trial), and safety (as measured by the incidence 
of adverse effects and withdrawal from the trial).21 Risk of bias was addressed in which the 
authors used only double-blinded studies. However, there was no further investigation on the 
degree to which the trials were double-blinded and the nature of the placebos was not stated in 
three of the studies.11  
The review included two studies that investigated SSRI’s in the treatment of depression 
in Alzheimer’s (Lyketsos 2003 and Petracca 2001).  The Lyketsos 2003 study produced two 
significant differences in favor of treatment with SSRI’s in the CSDD at 12 weeks (95% CI -11.50 – 
1.90) and in the psychiatrist’s global rating (Peto odds ratio (OR) (95% Fixed) 7.33 (2.20, 24.46)).11 
However, the meta-analysis showed a significant difference in favor of placebo (Peto OR (95% 
Fixed) 1.42 (1.07, 1.89), with patients experiencing at least one adverse event, such as one 
nervous system adverse event, gastrointestinal symptoms, and dry mouth with SSRI’s. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Summary of findings of treatment for depression with SSRI’s vs. Placebo  
 
(Rosenberg et al., 2010) 
 
Table 2. Proportion of participants with depression 
 
(Banerjee et al., 2016) 
 
Table 3. Odds ratio, the Neuropsychiatric Inventory (NPI) and derived factor scores 
  
(Banerjee et al., 2016) 
Table 3. Adverse reactions of SSRI’s by Week 39 of treatment 
 
(Banerjee et al., 2016) 
 
Table 4. Cochrane Risk of Bias Evaluation 
 Rosenberg et al., 2010 Banerjee et al., 2016 
Random sequence generation + + 
Allocation concealment + + 
Blinding of participants and 
personnel 
+ + 
Blinding of outcomes assessment + + 
Incomplete outcome data + + 
Selective reporting + - 
Other bias + + 
 
 
Discussion 
The study conducted by Rosenberg et al. (2010) showed that depression severity 
improved by nearly 50% (by CSDD scoring) with sertraline.  However, when compared with the 
placebo group (which also showed an improvement of depression severity), there was no 
significant difference.  The authors suggest that psychosocial intervention may have impacted 
study outcomes given the high rate of placebo response, which dilutes observed drug effect.19 
Another significant finding was that the sertraline group was associated with an increased 
incidence of adverse reactions, particularly those involving the respiratory system due to 
eosinophilic pneumonitis. Ultimately, the authors concluded that sertraline did not demonstrate 
efficacy for the treatment of depression in patients with AD and that SSRI’s may be of limited 
value for treating depression in patients with AD.19 
The study conducted by Banerjee et al. (2016) addressed barriers to their comprehensive 
study, particularly with regards to generalizability.  The researchers stated that “dropout 
introduced bias if those dropping out had a different response to the trial interventions or 
placebo compared with those completing the trial.”20 They also mentioned that their study may 
not generalize to those populations who are at high risk of suicide because that group cannot risk 
randomization.  Furthermore, the groups enlisted in their study are part of a specialist service for 
old-age psychiatry and do not include those with Alzheimer’s dementia who are in primary care 
facilities.   The authors concluded that antidepressants appear to be no more effect than placebo. 
The Cochrane Review mentions the complexity of diagnosing depression in patients with 
AD.  For instance, the DSM criteria for depression includes anhedonia and poor concentration, 
both symptoms of dementia.11 Sample size was also mentioned as a limiting factor for the clinical 
trials involving SSRI’s for the treatment of depression in patients with AD.  For instance, “there 
was a significant difference in favor of treatment compared with placebo in the CSDD at 12 weeks 
and in the psychiatrists’ global rating…[however], both of these results originate from a single 
study (Lyketsos 2003) with a small sample size (n = 44).”11 Thus, making the generalizability of 
SSRI’s in the treatment for depression in patients with AD questionable. 
 
Conclusion 
 Even though there was a lack of clinically significant outcomes in the trials between the 
use of SSRI’s vs. placebo in treating depression in Alzheimer’s disease, that does not mean that 
SSRI’s are ineffective.  SSRI’s have been the first-line treatment for many patients with depression 
due to their favorable risk-benefit ratio.23 There were a few key issues that were addressed 
among the trials.  Firstly, it is challenging to diagnose depression among patients with AD because 
symptoms such as difficulty concentrating and the inability to feel pleasure are also characteristic 
of both dementia and depression, making delineation difficult.  There have been some clinical 
trials in which cognitive functioning was a measure as to the efficacy of SSRI’s, however, this is 
non-specific to depressive symptoms. 
 In order to effectively begin treating depression in AD, we must use a standardized 
grading scale to diagnose depression that is specific in AD.  CSDD and the NIMH-dAD aim to be 
more specific guidelines to aid providers in diagnosing depression in Alzheimer’s.  Such measures 
include categories in mood-related signs (e.g. anxiety, sadness, lack of reactivity to pleasant 
events, irritability), behavioral disturbance (e.g. agitation, retardation, multiple physical 
complaints, loss of interest), physical signs (e.g. appetite loss, weight loss, lack of energy), cyclic 
functions (e.g. diurnal variation of mood, difficulty falling asleep, multiple awakenings during 
sleep, early morning awakening), and ideation disturbance (e.g. suicide, poor self-esteem, 
pessimism, mood-congruent delusions).22  
Another area of improvement for research in treating depression in AD is that there must 
be clinical trials with larger sample sizes to improve the generalizability of the findings.  Small 
sample sizes are problematic because they do not adequately represent the population of AD.  It 
was also mentioned that most of the participants in the study were part of a specialist service for 
old-age psychiatry and did not include those with Alzheimer’s dementia who are in other facilities 
or in the community.  Perhaps screening for depression in AD in the primary care setting can be 
included in future studies to address this issue. 
Studies have shown that there is higher morbidity and mortality for people with AD who 
have comorbid depression.  Further research on this topic becomes increasingly important 
because of the aging population in the world, as well as the growing number of people who are 
being diagnosed with AD annually. 
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